Skip to main content

Table 1 Patient characteristics

From: Stereotactic ablative body radiotherapy with a central high dose using CyberKnife for metastatic lung tumors

Factors

Value or number

Age

 Median, years (range)

69.2 (34.0–88.6)

Sex

 Male

55

 Female

57

PS

 0

82

 1

28

 2

2

Smoking status

 Current or previous smoker

52

 Never

40

 Unknown

20

History of irradiation to the chest

 Yes

23

 No

89

Primary site

 Uterus

35

 Colorectum

24

 Head and neck

17

 Esophagus

16

 Lung

8

 Pancreas

4

 Breast

3

 Bladder

1

 Stomach

1

 Liver

1

 Kidney

1

 Testicle

1

Histology

 SCC

47

 Adenocarcinoma (including endometrial adenocarcinoma)

41

 Sarcoma or carcinosarcoma

12

 Spindle cell carcinoma

2

 Ductal carcinoma

2

 Non-small cell carcinoma

2

 Transitional cell carcinoma

1

 Carcinoid

1

 Hepatocellular carcinoma

1

 Seminoma

1

 Clear cell carcinoma

1

 Large cell carcinoma

1

Chemotherapy within 3 months prior to irradiation

 Yes

29

 No

83

Tumor diameter

 Median (range), mm

11.5 (3.0–51.0)

Follow-up period

 Median (range), months

24.7 (4.0–87.7)

Dmax, Gy

 Median (range)

61.0 (55.1–97.2)

D99 of GTV, Gy

 Median (range)

50.1 (43.6–64.9)

D95 of PTV, Gy

 Median (range)

42.3 (39.4–55.9)

PTV volume, cm3

 Median (range)

11.6 (2–134.1)

  1. PS performance status, SCC squamous cell carcinoma, Dmax maximum radiation dose, D99 or D95 minimum dose that covered 99% or 95% of the target volume, respectively, GTV gross tumor volume, PTV planning target volume